AU2002300754B2 - New Combination - Google Patents

New Combination Download PDF

Info

Publication number
AU2002300754B2
AU2002300754B2 AU2002300754A AU2002300754A AU2002300754B2 AU 2002300754 B2 AU2002300754 B2 AU 2002300754B2 AU 2002300754 A AU2002300754 A AU 2002300754A AU 2002300754 A AU2002300754 A AU 2002300754A AU 2002300754 B2 AU2002300754 B2 AU 2002300754B2
Authority
AU
Australia
Prior art keywords
rheumatic
drug
methyl
inn
pde4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002300754A
Other languages
English (en)
Other versions
AU2002300754A1 (en
Inventor
Johannes Barsig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Takeda GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda GmbH filed Critical Takeda GmbH
Publication of AU2002300754A1 publication Critical patent/AU2002300754A1/en
Assigned to NYCOMED GMBH reassignment NYCOMED GMBH Request for Assignment Assignors: ALTANA PHARMA AG
Application granted granted Critical
Publication of AU2002300754B2 publication Critical patent/AU2002300754B2/en
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: NYCOMED GMBH
Assigned to TAKEDA GMBH reassignment TAKEDA GMBH Request to Amend Deed and Register Assignors: TAKEDA GMBH
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2002300754A 2001-11-09 2002-08-27 New Combination Ceased AU2002300754B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000607 2001-11-09
EP01000607.0 2001-11-09

Publications (2)

Publication Number Publication Date
AU2002300754A1 AU2002300754A1 (en) 2003-06-12
AU2002300754B2 true AU2002300754B2 (en) 2008-05-15

Family

ID=8176085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002300754A Ceased AU2002300754B2 (en) 2001-11-09 2002-08-27 New Combination

Country Status (6)

Country Link
US (2) US20030092706A1 (enExample)
EP (1) EP1448202A1 (enExample)
JP (1) JP2005508983A (enExample)
AU (1) AU2002300754B2 (enExample)
CA (1) CA2399840C (enExample)
WO (1) WO2003039552A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TR201815573T4 (tr) * 2002-05-28 2018-11-21 Astrazeneca Ab Topikal olarak uygulanabilir farmasötik preparasyon.
US6727272B1 (en) * 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
UA82323C2 (uk) * 2002-08-09 2008-04-10 Меда Фарма Гмбх & Ко. Кг Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань
DK1606261T3 (da) 2003-03-10 2010-01-18 Nycomed Gmbh Hidtil ukendt fremgangsmåde til fremstilling af roflumilast
US20070254928A1 (en) * 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
WO2006049215A1 (ja) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
WO2006099256A2 (en) * 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2006224619B2 (en) * 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
KR100838702B1 (ko) * 2007-02-08 2008-06-16 한국화학연구원 1-[1-(3,4-디알콕시아릴)-피리딜메틸]-1ｈ-피라졸 화합물의제조방법
US20100203146A1 (en) * 2009-02-09 2010-08-12 Callisto Pharmaceuticals, Inc. Intermittent dosing strategy for treating rheumatoid arthritis
US20150098993A1 (en) * 2011-07-28 2015-04-09 Shireen Vali Compositions, process of preparation of said compositions and method of treating inflammatory diseases
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
SG11201700243YA (en) 2014-08-06 2017-02-27 Pfizer Imidazopyridazine compounds
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1161239B1 (en) * 1999-03-10 2004-10-20 ALTANA Pharma AG 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis

Also Published As

Publication number Publication date
CA2399840A1 (en) 2003-05-09
CA2399840C (en) 2010-10-19
US20070270441A1 (en) 2007-11-22
WO2003039552A1 (en) 2003-05-15
JP2005508983A (ja) 2005-04-07
EP1448202A1 (en) 2004-08-25
US20030092706A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
US20070270441A1 (en) Combination
MXPA01003855A (es) Combinaciones de antagonistas del factor de liberacion de corticotropina y secretagogos de hormona del crecimiento.
TW200538128A (en) Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists
JP7174175B2 (ja) 近視の治療、近視の予防および／または近視の進行抑制のための医薬
TW200423932A (en) Combination of a PDE IV inhibitor and a TNF-alpha antagonist
US10842778B2 (en) Use and composition for treating myasthenia gravis and other myasthenic syndromes
CA2478612C (en) Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist
EP4531856B1 (en) Bruton's kinase inhibitors for the treatment of a sudden allergic reaction
AU2018290288A1 (en) Epichaperome inhibitor therapy for traumatic brain injury and sequelae thereof
KR20230171918A (ko) 소아-발병 유창성 장애의 치료 방법
WO2018140412A1 (en) Neostigmine combination and compositions
KR20190127885A (ko) 활성 성분으로서 티오트로피움을 포함하는, 근시 예방, 근시 치료, 및/또는 근시 진행 예방을 위한 제제
WO2020014072A1 (en) Neostigmine pharmaceutical combination for treating myasthenia gravis
CN117157077A (zh) 儿童期发病的流畅性障碍的治疗方法
WO2026000074A1 (en) Use of cd38 inhibitors for reducing th2 inflammation
HK40114766A (zh) 用於治疗睡眠呼吸暂停的task1/3通道阻断剂与毒蕈碱型受体拮抗剂的结合物
CZ2003234A3 (cs) 2-Aryl-8-oxodihydropurinové deriváty jako léčivo
WO2019023318A1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA
JPWO2002010167A1 (ja) ２−アリール−８−オキソジヒドロプリン誘導体を有効成分とする痴呆症治療剤
WO2009023122A1 (en) Cobalamin regimens for the treatment of nitrogen oxide-mediated conditions
EA044096B1 (ru) Применения ингибитора лизилоксидаза-подобного белка 2
JP2002249443A (ja) 情緒障害予防・治療薬
JP2003063988A (ja) Ｐｄｅ阻害剤を有効成分として含有する脊髄小脳変性症治療剤
JPWO2001022997A1 (ja) 鎮痛薬

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 16, NO 31, PAGE(S) 263 UNDER THE HEADING COMPLETE APPLICATIONS FILED - NAME INDEX UNDER THE NAME ALTANA PHARMA AG, APPLICATION NO. 2002300754, UNDER INID (33) CORRECT THE COUNTRY CODE TO READ EP.

TC Change of applicant's name (sec. 104)

Owner name: NYCOMED GMBH

Free format text: FORMER NAME: ALTANA PHARMA AG

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PATENTEE TO READ TAKEDA GMBH .

MK14 Patent ceased section 143(a) (annual fees not paid) or expired